Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY

We have already crossed the halfway mark of the second-quarter reporting cycle. The earning season has shown broad-based growth with record earnings this quarter.

As of Jul 28, 2017, 286 S&P 500 members, accounting for 68.8% of the index’s total market capitalization, reported results, according to Earnings Preview. Of these, 57.7% companies beat both on both counts compared with 55.6% in the first quarter.

Total earnings for these 286 index members were up 11.3% from the year-ago quarter on a 6.1% improvement in revenues. The beat ratio was 74.5% for earnings and 69.2% for revenues. The Medical segment has also performed well so far with earnings up 6% on 4.7% increase in revenues.

Per the report, total earnings for S&P 500 companies in the second quarter are expected to grow 9.2% year over year on 5% higher revenues. With plenty of results still to come, the actual earnings growth this quarter may exceed the 10% mark. This follows 13.3% earnings growth in the first quarter on 7% increase in revenues, the highest in almost two years.

Johnson & Johnson JNJ began the earnings season for the pharma sector with mixed second-quarter results. Performance of Novartis NVS, Lilly LLY and Biogen Inc. BIIB were encouraging as the companies beat both earnings and revenue estimates. Lilly and Biogen also raised their earnings and revenue estimates for 2017. Among other pharma bigwigs which reported last week, AbbVie Inc. ABBV reported better-than-expected results with both earnings and sales surpassing expectations. Its lymphoma drug, Imbruvica recorded record growth. Merck & Co., Inc. MRK also beat estimates for both earnings and sales in the second quarter mainly backed by strong sales of PD-1 inhibitor, Keytruda.

Let’s take a look at three pharma/biotech companies that are set to report second-quarter results on Aug 1. Let's see how things are shaping up for this quarter.

Pfizer Inc. (PFE)

Pfizer, which is scheduled to release earnings before the opening bell, delivered a positive earnings surprise of 2.99% last quarter. Pfizer’s earnings performance has been mixed with earnings missing expectations in two of the last four quarters and beating the same twice, resulting in an average negative surprise of 0.35%.

For this quarter, Pfizer has an http://www.zacks.com/earnings/earnings-surprise-predictions/">Earnings ESP of +1.54% and a Zacks Rank #3 (Hold), indicating a likely beat. The Zacks Consensus Estimate is pegged at 65 cents per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Pfizer, Inc. Price and EPS Surprise

Pfizer, Inc. Price and EPS Surprise | Pfizer, Inc. Quote

New products like Xeljanz (rheumatoid arthritis) and Ibrance (breast cancer) as well as older products like Lyrica (neuropathic pain) and Eliquis (blood thinner) are likely to contribute to the top line meaningfully. (Read More: Is a Beat in the Cards for Pfizer  in Q2 Earnings?).

Aerie Pharmaceuticals, Inc. (AERI)

Aerie Pharma is scheduled to announce results after the closing bell. Aerie Pharma has missed estimates in each of the past four quarters and has an average negative earnings surprise of 17.07%.

The company has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

With no approved product in its portfolio, Aerie depends heavily on its late-stage candidates-Rhopressa and Roclatan. Aerie has submitted regulatory application for Rhopressa in the U.S. and expects to submit the same in the EU in the second half of 2017. Hence, we expect investor focus to remain on pipeline updates. (Read More: What's in the Cards for Aerie This Earnings Season?)

Incyte Corporation (INCY)

The company is expected to report before market opens. Incyte delivered an earnings surprise of 1.03% last quarter. Incyte’s performance has been pretty impressive, with the company reporting positive surprise consistently. The average earnings beat over the last four quarters is 336.06%.

The company has an Earnings ESP of -37.5% and a Zacks Rank #3. The Zacks Consensus Estimate is pegged at a loss of 8 cents per share.

Incyte Corporation Price and EPS Surprise

Incyte Corporation Price and EPS Surprise | Incyte Corporation Quote

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer, Inc. (PFE): Free Stock Analysis Report
 
Eli Lilly and Company (LLY): Free Stock Analysis Report
 
Novartis AG (NVS): Free Stock Analysis Report
 
Johnson & Johnson (JNJ): Free Stock Analysis Report
 
Merck & Company, Inc. (MRK): Free Stock Analysis Report
 
AbbVie Inc. (ABBV): Free Stock Analysis Report
 
Incyte Corporation (INCY): Free Stock Analysis Report
 
Biogen Inc. (BIIB): Free Stock Analysis Report
 
Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.